<DOC>
	<DOCNO>NCT02504255</DOCNO>
	<brief_summary>Crohn disease ( CD ) usually evolve surge intersperse period unpredictable remission . probability recurrence CD patient remission even strong pre-exists endoscopic lesion intestinal mucosa . The mucosal heal exploration need realization ileo-colonoscopy general anesthesia invasive procedure , restrictive expensive , thus prohibit frequent repetition . currently noninvasive reliable marker able predict occurrence thrust CD allow introduction suitable treatment . Indeed , relapse prevention best way avoid complication formation lesion lead irreversible medical treatment failure surgery . Since CD , immunological change lead inflammation lesion , make assumption ability certain marker immunological predict relapse CD high particular inflammatory marker . This work help identify profile patient CD remission high risk recurrence . It specify ) potential new marker immunological , pre-clinical research , predict onset recurrence CD ; ii ) predictive interest different inflammatory marker use routine CD evaluation ; iii ) Finally , stress management stressful event occurrence relapse . This work also specify evolution different marker moment thrust</brief_summary>
	<brief_title>Evaluation Immunological Markers , Inflammatory Clinical Relapse Psychological Predictive During Crohn 's Disease</brief_title>
	<detailed_description />
	<mesh_term>Crohn Disease</mesh_term>
	<criteria>Patient 18 year . Patient CD previously diagnose accord standard criterion . Patient remission ( HBS≤4 ) least 3 month receive corticosteroid ( include budesonide ) 3 month . Patient without concomitant treatment Crohn 's disease stable dose ( 5ASA , corticosteroid , immunosuppressant , antiTNF ) immunosuppressant ( azathioprine , Purinethol , methotrexate ) / antiTNF / 5 amino salicylate ( 5ASA ) least 6 month . Patient sign consent . Patient affiliate social security scheme . A patient active CD ( HB score≥5 ) . Patient relapse previous three month inclusion . Patient receive corticosteroid ( include budesonide ) 6 month prior inclusion . Patients stable dose nonantiTNF 6 month prior inclusion . Patient take nonsteroidal antiinflammatory drug antibiotic . Patient complication intestinal subocclusion type fistulas abdominal abscess . Patient exclusive perianal disease predominate perianal manifestation . Pregnant woman ( examination ) . Patient subject extensive intestinal resection ( &gt; 1 ) . Patient ileostomy colostomy . Patient legal protection measure legal capacity consent Lack sign write consent patient .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2015</verification_date>
	<keyword>Crohn disease</keyword>
	<keyword>inflammatory biomarkers</keyword>
	<keyword>immunologic marker</keyword>
	<keyword>calprotectin</keyword>
</DOC>